Sionna Therapeutics Share Price Today: Live Updates & Key Insights

Sionna Therapeutics share price today is $36.45, up 2.54%. The stock opened at $35.32 against the previous close of $35.49, with an intraday high of $37.37 and low of $35.32.

Sionna Therapeutics Share Price Chart

Sionna Therapeutics

us-stock
To Invest in {{usstockname}}
us-stock

Sionna Therapeutics Share Price Performance

$36.45 0.0254(2.54%) SION at 23 Mar 2026 03:13 PM Biotechnology
Lowest Today 35.32
Highest Today 37.37
Today’s Open 35.32
Prev. Close 35.49
52 Week High 45.00
52 Week Low 7.26
Day’s Range: Low 35.32 High 37.37
52-Week Range: Low 7.26 High 45.00
1 day return -
1 Week return -2.52
1 month return +0.77
3 month return -14.21
6 month return +39.6
1 year return +201.32
3 year return -
5 year return -
10 year return -

Sionna Therapeutics Institutional Holdings

Sionna Therapeutics Market Status

Strong Buy: 3

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Sionna Therapeutics Fundamentals

Market Cap 1637.48 M

PB Ratio 5.3367

PE Ratio 0.0

Enterprise Value 1410.27 M

Total Assets 325.95 M

Volume 339158

Sionna Therapeutics Company Financials

About Sionna Therapeutics & investment objective

Company Information Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Organisation Biotechnology

Employees 59

Industry Biotechnology

CEO Mr. Michael Cloonan M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Sionna Therapeutics FAQs

What is the share price of Sionna Therapeutics today?

The current share price of Sionna Therapeutics is $36.45.

Can I buy Sionna Therapeutics shares in India?

Yes, Indian investors can buy Sionna Therapeutics shares by opening an international trading and demat account with Motilal Oswal.

How to buy Sionna Therapeutics shares in India?

You can easily invest in Sionna Therapeutics shares from India by:

Can I buy fractional shares of Sionna Therapeutics?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Sionna Therapeutics?

Sionna Therapeutics has a market cap of $1637.48 M.

In which sector does Sionna Therapeutics belong?

Sionna Therapeutics operates in the Biotechnology sector.

What documents are required to invest in Sionna Therapeutics stocks?

To invest, you typically need:

What is the PE and PB ratio of Sionna Therapeutics?

The PE ratio of Sionna Therapeutics is N/A and the PB ratio is 5.34.